51,661 Shares in DexCom, Inc. $DXCM Purchased by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 51,661 shares of the medical device company’s stock, valued at approximately $3,476,000.

Several other hedge funds have also added to or reduced their stakes in the stock. Andra AP fonden bought a new position in shares of DexCom during the 2nd quarter valued at approximately $26,000. Twin Peaks Wealth Advisors LLC purchased a new position in DexCom in the second quarter valued at approximately $26,000. SJS Investment Consulting Inc. grew its holdings in DexCom by 4,800.0% during the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 384 shares during the period. Financial Consulate Inc. purchased a new stake in DexCom in the third quarter worth $29,000. Finally, Sound Income Strategies LLC raised its stake in shares of DexCom by 83.8% in the third quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock valued at $43,000 after buying an additional 285 shares during the period. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Leerink Partners reaffirmed an “outperform” rating and set a $92.00 price target on shares of DexCom in a research report on Tuesday, December 16th. Morgan Stanley reaffirmed an “overweight” rating on shares of DexCom in a report on Monday, January 12th. UBS Group cut their target price on shares of DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, November 3rd. Evercore started coverage on shares of DexCom in a research report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 price target on the stock. Finally, Truist Financial restated a “buy” rating and set a $80.00 price target (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $85.18.

DexCom Stock Up 1.1%

DXCM stock opened at $73.08 on Friday. The stock has a 50-day simple moving average of $69.49 and a two-hundred day simple moving average of $69.31. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $91.87. The firm has a market capitalization of $28.13 billion, a PE ratio of 34.80, a PEG ratio of 1.42 and a beta of 1.49. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. The company had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. DexCom’s revenue was up 13.1% compared to the same quarter last year. During the same period last year, the business earned $0.45 earnings per share. On average, equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.